Wednesday, May 24, 2023

3:00 PM - 3:45 PM

Hall M

---

Details

Reimbursement of medical technology has always been critical to enabling early access and equally critical to enabling broad access as the technology matures. In recent years we have seen a high profile and antagonistic battle over the Prostheses List which continues into the current Budget cycle. With the unexpected and unprecedented costs of managing the pandemic, health funders, in particularly governments, will face constraints in healthcare expenditure in the coming years. What do medtech companies need to consider in their reimbursement strategies in 2023 and beyond?

---

Speaker